Anavex Life Sciences Corp (AVXL)

[Investor2014]

Anavex Life Sciences (AVXL) Q3 2022 Earnings Call Transcript

Soumit Roy -- Jones Research -- Analyst

I see. Totally understandable. And last question. So you are still -- curious where you are currently on whether to file the adult BLA separately from pediatric BLA.

Or do you want to wait until the entire pediatric data is available and then file it together? Any thoughts on that?

Christopher Missling -- President and Chief Executive Officer

At this point, we are so close to readout of the EXCELLENCE study. And we should remind everyone that Rett syndrome is a pediatric indication predominantly. It is a study in -- it's an indication which affects girls from an early age onwards, and many patients die when they get older. The life expectancy at 40 years is only 50%.

And so that makes it clear that is a pediatric indication predominantly. That's why also we focused on the study size, and the study focused on the pediatric study. And the adult study is important to get approval for the entire age group. And at this point in time, we also want to make sure that since we have the voucher eligibility, we want to make sure that we are able to submit a successful pediatric study first in order to receive this voucher, which is quite valuable, as you know.

So again -- but the key thing is that we are so far into this EXCELLENCE study that it is just more preferred and prudent in addition to the fact that it's predominantly a pediatric indication, to finish the EXCELLENCE study and then file the entire program, which consists of three placebo-controlled study, the Phase 2, the Phase 3 AVATAR and the Phase 3 EXCELLENCE study.